Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in
Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer

IRB/UVA Tracking #
20518
Contact
Jake Boyd
Contact Email
Contact Phone
1.434.243.0425
Phase
I/II
Primary purpose
Treatment
Cancer PI
Patrick M Dillon
Status
OPEN TO ACCRUAL
Ages
Adult